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SUPERIOR COURT
CIVIL ACTION
Docket No. (\ \f - 11 -

STATE OF MAINE
KENNEBEC, SS.
STATE OF MAINE

Plaintiff,
v.
ASTRAZENECA PHARMACEUTICALS LP,
and
ASTRAZENECA LP

)
)
)
)
)
)
)
)
>
)
)
>

FINAL JUDGMENT AND
CONSENT DECREE

Defendants

Plaintiff, the State of Maine, i?y its Attorney General William J. Schneider, has filed a
Complaint for a permanent injunction and other relief in this matter pursuant to the Maine Unfair
Trade Practices Act, 5 M.R.S. § 205-A et seq,, alleging that AstraZeneca Pharmaceuticals LP

Plaintiff, by its counsel, and AstraZeneca Pharmaceuticals LP and AstraZeneca LP, by
their Counsel, have agreed to the entry o f this Final Judgment and Consent Decree (‘‘Judgment”)
by the Court without trial or adjudication of any issue of fact or law or finding of wrongdoing or
liability of any kind.
PARTIES
1.

The State of Maine (hereinafter “the State”) is the Plaintiff in this case. The

Maine Attorney General is charged with, among other things, the responsibility of enforcing the
Maine Unfair Trade Practices Act.
2.

AstraZeneca Pharmaceuticals LP and AstraZeneca LP (hereinafter

“AstraZeneca”) are the Defendants in this case. AstraZeneca’s Corporate Headquarters is located
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I.

at, 1800 Concord Pike, Wilmington, DE 19850-5437, As used herein, any reference to
“AstraZeneca” shall mean AstraZeneca Pharmaceuticals LP and AstraZeneca LP.
TRADE AND COMMERCE
AstraZeneca, at all times relevant hereto, engaged in trade and commerce affecting
consumers, within the meaning of the Maine Unfair Trade Practices Act, in the State of Maine.
PREAMBLE
A.

The Attorneys General of thirty seven1states and the District of Columbia

(collectively, the “Attorneys General,” and the “AGs”),2 conducted an investigation regarding
certain AstraZeneca practices concerning Seroquel.
B.

The Parties have agreed to resolve the claims raised by the Covered Conduct, as

set forth in Section VII, by entering into this Judgment. This Judgment is enteiecl into pursuant
to and subject to the State consumer protection laws3*5cited in footnote 3.

1Arizona, Califtxpià* Colorado, Connecticut, Delaware, Florida, Hawaii, Idaho,- minois; Iowa, Kansas, Louisiana, Mairie, Maryland,
Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, Neyt*York, North Carolina, North Dakota,
Ohio* Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont Washington, West Virginia and Wisconsin.
2 Hawaii is being represented on this matter by its Office of Consumer Protection, an agency which is not partof the state.Attorney General’s
Office, but which is statutorily authorized to undertake consumer protection functions, including legal representation of die State of Hawaii. For
simplicity, die entire group will be referred to as thé “Attorneys General,” and such designation, as it includes Hawaii, refers to the Execitive
Director of the State Of Hawaii Office of Consumer Protection”
3 ARIZONA—Arizona Consumer Fraud.Act* A.R.S. § 44-1521 etseq,; CALIFORNIA - Bus. & ProfCodc §§ 17200 e/ seq. and 17500 et 'sèq.;
COLORADO - Colorado Consumer Protection. Act, Colo. Rev. S&t § 6>Li01 etséq.; CONNECTICUT - Connecticut Unfair- Trade Practices
Act, Conn. Gen. Stat §§ 42-1 l6.a et seq.; DELAWARE - Delaware Consumerfraud Act, Del. CODE ANN, tit., 6, §§ 2511 to-2527; DISTRICT
OF COLUMBIA* District ofÇolumbiq Consumer Protection Procedures AcfD.C. Code §§ 28-3901 et s e q FLORIDA - Florida Deceptive and
Unfair Trade Practices Act, Part If, Chapter 501, Florida Statutes, 501.201 el. seq,', HAWAII Uniform Deceptive Trade Practice Ad, Haw'.
ReV. Stat. Chpt 481Aand Haw. 501.201 etseq,;IDAHO - Consumer Protection Act, Idaho Code Section.48-601 et seq/; ILLINOIS - Consumer
Fraud and Deceptive Business Practices Act, 815 ILCS 505/2 et seq.; IOWA r- Iowa Consumer Fraud.Act, lovya Code Section 714,16; KANSAS
- Kansas Consumer Protection Act, K.S.A. 50-623 et seq,; LOUISIANA - Unfair Trade-Practices and Consumer Protection Law, LSÀ-RS.
5 !: 1401, et seq.; MAINE - Unfair Trade Practices Act, 5 M.R.S, § 207 et seq,; MARYLAND - Maryland Consumer Protection.Act\ Md, Code
Arm., Com. Law §§ 13-101 et seq.; MASSACHUSETTS - Mass. Gen. Lawsc. 93A, §§ 2 and 4; MICHIGAN - Michigan. Consumer Protection
Act, MCI, § 445.901 et seq,; MINNESOTA - Minnesota Deceptive Trade Practices Act, Minn. Stat §§ 325D.43-48; Minnesota False Advertising
Act Minn. Stat § 325F.67; Minnesota Consumer Fraud Act, Minn. Stat. §§ 325F.68-70; Minnesota Deceptive Trade Practices Against Senior
Citizens or Disabled Persons Act, Minn, Stat § 325F.7L; MISSOURI - Missouri Merchandising PracticesAçt, Mù. Rev, Stat §§ 407 et seq.;
NEBRASKA —Uniform.Deceptive Trade Practices Act, NRS §§ 87-301 et seq.; NEVADA—Deoepdye Trade Practices. Act,. Nevada'Revised
Statutes 598.0903 et seq.;MEW HAMPSHIRE - Vew Hampshire ConsumerProtection Act, RSA 3'58'-A; NJBWJERSEY -New Jersey
Consumer Fraud Act, NJSA 56:8-1 et seq.; NEW YORK - General Business Law Art.22-A, §§349-50, arid Executive Law' § 63(12); NORTH
CAROLINA- North. Carolina* Unfair and Deceptive Trade Practices Act, N.Ç.O.S. 75-1.1, et seq.; NORTH DAKOTA - Unlawful Sales or
Advertising Practices, N.D. Cent. Code § 51-15,-02 et seq.; OHIO - Ohio Consumer Sales Practices Act, R.C. 1345.01, et seq.; OKLAHOMA Oklahoma Consumer Protection Act 15 O.S. §§ 751 et seq.; OREGON *■Oregon Unlawful Trade Practices Act, ORS 646.605 et seq.;
PENNSYLVANIA- Pennsylvania Unfair Trade Practices and Consumer Protection lent, 73 P.S- 201-1 el seq.; RHODE ISLAND - Rhode
Island Deceptive Trade Practices Act, Rhode Island General Laws § 6-13. l-l, et seq.; SOUTH DAKOTA - South Dakota Deceptive Trade
Practices and Consumer Protection, SDCL ch. 37-24; TENNESSEE - Tennessee Consumer Protection Act, Term. Code Ann. 47-18-101 et seq.;
TEXAS1- Texas Deceptive Trade Practices-Consumer Protection Act, Tex. Bus. And Com. Code 17.47,- etseq.; VERMONT - Consumer Fraud
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AstraZeneca is entering into this Judgment solely for the purpose of settlement

and nothing contained herein may be taken as or construed to be an admission or concession of
any violation of law or regulation, or of any other matter o f fact or law, or of any liability or
wrongdoing (including allegations of the Complaint), all of which AstraZeneca expressly denies,
AstraZeneca does not admit any violation of law, and does not admit any wrongdoing that was or
could have been alleged by any Attorney General before the date of the Judgment. No part of this
Judgment, including its statements and commitments, shall constitute evidence of any liability,
fault, qf wrongdoing by AstraZeneca. This Judgment is made without trial or adjudication of
any issue of fact or law or finding of wrongdoing or liability qf any kind. It is the intent of the
Parties that this Judgment shall not be binding or admissible in any other matter, including, but
npt limited to, any investigation o r litigation, other than in connection with the enforcement of
this Judgment; No part of this Judgment shall create a private cause o f action or confer any right
to any third party for violation o f any federal or state statute except that a State may file an action
to enforce the terms of this Judgment. To the extent that any provision of tins Judgment
obligates AstraZeneca to change any policy(ies) or procedure(s) and to the extent not already
accomplished, AstraZeneca shall implement the policy(ies) or prpcedure(s) as soon as reasonably
practicable, but no later than 120 days after the Effective Date of this Judgment. Nothing
contained herein prevents or prohibits the use of this Judgment for purposes of enforcement by
the AGs.
D.

Tins Judgment does not create a waiver or limit AstraZeneca’s legal rights,

remedies* or defenses in any other action by the Signatory Attorney General, and does not waive
Act, 9 V.S.A. §§ 2451 etseqr, WASHINGTON*- Unfair Business Practices/Consumer Protection Actf RCW §§. 19.86 etseq.\ WEST VIRGINIA
—West Virginia Consumer Credit and Protection Act, W. Va. Code § 46A-1101 et seq.; WISCONSIN —Wis. Stat § 100.18 (Fraudulent
Representations).
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or limit AstraZeneca’s right to defend itself from, or make argument in, any other matter, claim,
or suit, including, but not limited to any investigation or litigation relating to the existence,
subject matter, or terms of this Judgment. Nothing in this Judgment shall waive, release, or
otherwise affect any claims, defense, or positions AstraZeneca may have in connection with any
investigations, claims, or other matters the State is not releasing hereunder.
E.

The Attorneys General have reviewed the terms of the Judgment and find that its .

entry serves the public interest,
IT IS HEREBY ORDERED that:
DEFINITIONS
The following definitions shall be used in construing this Judgment:
1.

“AstraZeneca” shall mean “AstraZeneca Pharmaceuticals LP” and “AstraZeneca

LP,” including all of their subsidiaries, divisions, successors, and assigns doing business in the
United States.
2.

“AstraZeneca’s Legal Department” shall mean personnel of the AstraZeneca

Legal Department or its designee providing legal advice to AstraZeneca.
3.

“AstraZeneca Marketing” shall mean AstraZeneca commercial personnel

assigned to the U.S. Seroquel brand team.
4.

“AstraZeneca Medical Education Grants Office” and “MEGO” shall mean the

U.S.-based organization within AstraZeneca responsible for oversight of medical education
grants and the acceptance, review, and payment of all medical education grant requests.
5.

“AstraZeneca Non-SciP” shall mean AstraZeneca personnel other than

AstraZeneca Scientifically Trained Personnel or SciP.
6.

“AstraZeneca Sales” shall mean the AstraZeneca pharmaceutical sales

specialists, or other AstraZeneca personnel, responsible for U.S. Seroquel sales.
4
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7.

“AstraZeneca Scientifically Trained Personnel” or “SciP” shall mean AstraZeneca

personnel who are highly trained experts with specialized scientific and medical knowledge
whose roles involve the provision of specialized medical or scientific information, but excludes
anyone performing sales, marketing, ride alongs, or other commercial roles.
8.

“Clinically Relevant Information" shall mean information that reasonably prudent

clinicians would consider relevant when making prescribing decisions regarding Seroquel.
9.

“Consultant” shall mean a non-AstraZeneca Health Care Professional engaged to

advise regarding marketing or promotion ôf Seroquèl.
1(>.

“Covered Conduct” shall mean AstraZeneca’sPro motional and marketing

practices, sampling practices, dissemination o f information (including clinical research results),
and remuneration to Health Care Professionals, in connection with Seroquel through the
Effective Date of the Judgment.
11.

“Effective Date” shalLmean the date on which a copy of this Judgment, duly

executed by AstraZeneca and by the Signatory Attorney General, is approved by, and becomes a
Judgment of the Court.
12.

“FDA Guidances for Industry” shall mean draft or final documents published by

the United States Department Of Health and Human Services, Food and Drug Administration
(“FDA”) that represent the FDA’s current thinking on a topic.
13.

“Health Care Professional” or “HCP” shall mean any physician or other health

care practitioner who is licensed to provide health care services or to prescribe pharmaceutical
products in the United States.
14.

“Labeling” shall mean all FDA-approyed labels, which are a display o f written,

printed, or graphic matter upon the immediate container of any article, and other written, printed,
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or graphic matter (a) upon any article or any o f its containers or wrappers, or (b) accompanying
such article.
15.

“Multistate Executive Committee” shall mean the Attorneys General and their

staffs representing Arizona, Delaware, District o f Columbia, Florida, Illinois, Kansas, Maryland,
Massachusetts, North Carolina, Ohio, Pennsylvania, and Vermont
16.

“Multistate Working Group” shall mean the Attorneys General and their staff

representing Arizona, California, Colorado, Connecticut, Delaware, District of Columbia,
Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts,
Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York,
North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South
Dakota, Tennessee, Texas, Vermont, Washington, West Virginia, and Wisconsin.
17.

“Off-Label” shall mean a use not Consistent with the indications section of the

Seroquel Labeling approved by the FDA at the time information regarding such use was
communicated.
18.

“Parties” shall mean AstraZeneca and the Signatory Attorney General.

19.

“Professional Information Request Response” or “PIR Response” shall mean a

rion-promotional, scientific or reference communication to address Unsolicited Requests for
medical information from HCPs.
2D.

“Promotional,” “Promoting” or “Promote” shall mean representations made to

HCPs, patients, consumers, payers and other customers and other practices intended to increase
sales or that attempt to influence prescribing practices o f HCPs.
21.

“Promotional Slide Deck” shall mean Promotional materials in any medium

regarding Seroquel for use in speaker programs in the United States,
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22.

i

“Promotional Speaker” shall mean a HOP speaker engaged to Promote Seroquel

in the United States.
23.

‘‘Reprints Containing Off-Label Information” shall mean articles or reprints from

a Scientific or Medical Journal, as defined in 21 C.F.R. 99.3(j), or Reference Publication, as
defined in 21 C.F.R. 99.3(i), describing an Off-Label use of Seroquel.
24.

“Seroquel” shall mean all FDA-approved drug formulations containing quetiapine

fumarate as its principal active ingredient and Promoted by AstraZeneca in the United States,
including Seroquel XR.
25.

“Signatory Attorney General” shall mean the Attorney General o f Maine, or her

authorized designee, who has agreed to this Judgment.
26.

'

,

'Unsolicited Request” shall mean a request for information regarding Seroquel

from a HCP communicated to an agent of AstraZeneca that has not been prompted by
AstraZeneca.
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COMPLIANCE PROVISIONS
Except for Sections LA-C, LE G, II.A, II.D .l, IV, and V below, the Compliance
Provisions shall apply for six (6) years from the Effective Date of this Judgment
I.

Prom otional Activities
A.

AstraZeneca shall not make any written or oral claim that is false, misleading or

deceptive regarding Seroquel.
B.

AstraZeneca shall not Promote Seroquel for Off-Label uses.

C.

In Promotional materials for Seroquel, AstraZeneca; shall clearly and

conspicuously disclose the risks associated with the product as set forth in the product" s black
box warning and shall present information about effectiveness and risk in a balanced manner.
D.

AstraZeneca shall not present patient profiles/types based on selected symptoms

of tiie FDA-approved indication(s) when Promoting Seroquel, unless:
1.

The drug’s specific FDA-approved indication(s) is/are stated clearly and

conspicuously in the same spread (ie., on the same page or on a facing page) in any Promotional
materials that refer to selected symptoms,
a.

With respect to Promotional Slide Decks:
(i)

AstraZeneca shall state clearly arid conspicuously the
FDA-approved indication^) on the same slide in which
selected symptoms are first presented;

(ii)

AstraZeneca shall include a short-hand reference to the
statement described in Section LD. La.(i) on the same
slide as each subsequent reference to selected symptoms
(e.g., “Seroquel is not approved for X selected symptom
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referenced in this slide. See list of FDA-approved
indications at p. Y”); and,
(iii)

AstraZeneca shall require any presenter of AstraZeneca's
Promotional Slide Decks to present the statement
required in Section I.D. 1.a.(i), as part of the mandatory
slides,

2.

Promotional materials have a reference indicating that the full

constellation of symptoms and the relevant diagnostic criteria should he consulted and are
available in the Diagnostic and Statistical Manual o f Mental Disorders (DSM-IV or current
version), where applicable.
E.

AstraZeneca shall ensure that all Promotional Speakers' Promotional materials

for Seroquei comply with AstraZeneca's obligations in the above Sections I.A-D.
F.

AstraZeneca's systems and controls shall 1) be designed to ensure that

financial incentives do not motivate AstraZeneca Marketing and/or Sales personnel to engage in
improper promotion, sales, andmarketing o f Seroquei; and 2) include mechanisms to exclude from
incentive compensation sales that may indicate Off-Label promotion of Seroquei.
G.

AstraZeneca's systems and controls shall be designed to prevent AstraZeneca

Sales from detailing Seroquei to HCPs who are unlikely to prescribe Seroquei for a use
consistent with its FDA-approved label. This shall be effected through systems and controls
requiring that AstraZeneca review the call plan$ for Seroquei and the bases upon, and
circumstances under which HCPs belonging to specified medical specialties or types of clinical
practice are included in, or excluded from, the call plans. The systems and controls shall
require that AstraZeneca modify the call plans as necessary to ensure that AstraZeneca is

9

Promoting Seroquel in a manner that complies with applicable Federal health care program and
FDA requirements.
H.

AstraZeneca’s detailing systems and its controls shall prevent the delivery of

samples of Seroquel to HCPs that AstraZeneca has identified as belonging to a specialty group
that is unlikely to prescribe Seroquel for a use consistent with its FDA-approved label.
II.

Dissemination axid Exchange of Medical Information
A*

General Terms
I.

The content of AstraZeneca’s communications concerning Off-Label uses

of Seroquel shall not be false, misleading or deceptive.;
B.

Professional Information Request Responses
1.

AstraZeneca Scientifically Trained Personnel shall have ultimate

responsibility for developing and approving the medical content for all PIR Responses regarding.
Seroquel, including any that may describe Off-Label information. AstraZeneca shall not
distribute airy such materials unless:
a-

Clinically Relevant Information is included in these materials to
provide scientific balance;

b.

Data in these materials are presented in an unbiased; noiiPromotional manner; and

c.

These materials are distinguishable from sales aids and other
Promotional materials.

2,

AstraZeneca Sales and AstraZeneca Marketing personnel shall not

develop the medical content of PIR Responses regarding Seroquel.
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3.

AstraZeneca Sales representatives shall not distribute PIR Responses

regarding Seroquel unless specifically authorized to do so pursuant to II.C.6.
4.

AstraZeneca shall not knowingly disseminate any PIR Response

describing any Off-Label use of Seroquel that makes any false, misleading or deceptive
representation regarding Seroquel or any false or misleading or deceptive statement concerning a
competing product
C.

Responses to Unsolicited Requests for Off-Label information
I.

In responding to an Unsolicited Request for Off-Label information

regarding Seroquel, including any request for a specific article related to Off-Label uses,
AstraZeneca shall advise the requestor that the request concerns an Off-Label use and inform the
requestor of the drug’s FDA-approved indicafion(s), dosage and other relevant Labeling
information,
2*

If AstraZeneca elects to respond to an Unsolicited Request for Off-Label

information from a HCP regarding Seroquel, AstraZeneca Scientifically Trained Personnel shall
provide accurate, objective, and scientifically balanced responses. Any such response shall not
Promote Seroquel for an Off-Label use.
3,

Any written response to an Unsolicited Request for Off-Label information

made to AstraZeneca Sales or AstraZeneca Marketing regarding Seroquel shall include:
a.

an existing PIR Response prepared in accordance with Section
ILB;

b.

a PIR Response prepared in response to the request in accordance
with Section ILB; or
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c.

a report containing the results of a reasonable literature search
using terms from the request.

4.

Only AstraZeneca Scientifically Trained Personnel may respond in writing

to an Unsolicited Request for Off-Label information regarding Seroquel unless AstraZeneca
Non-SciP are specifically authorized to do so pursuant to II.C.6.
5.

AstraZeneca Non-SciP may respond orally to an Unsolicited Request for

Off-Label information regarding SeroqUel from a HCP only by offering to request on behalf of
the HCP that a PIR Response or other information set forth above in ILC.3 be sent to the HCP in
follow up or by offering to put the HCP in touch with the Virtual Scientific Exchange Center
(“VSEC”). AstraZeneca Non-SciP shall not characterize, describe* identify, name, or offer any
opinions about or summarize any Off-Label information.
6.

PIR Responses regarding Seroquel may be disseminated only by

AstraZeneca Scientifically Trained Personnel to HCPs, and AstraZeneca Non-SciP shall not
disseminate these materials to HCPs except in circumstances implicating public health and safety
issues. In such circumstances, AstraZeneca Non-SciP may disseminate a PIR Response directly
to HCPs, when expressly authorized by the U.S. Compliance Officer, the U.S. General Counsel,
and the Vice President of Medical Affairs.
*

D.

n

Reprints
1.

AstraZeneca shall not disseminate information or written materials

describing Off-Label or unapproved uses of Seroquel unless such information and materials
comply with applicable FDA regulations and FDA Guidance for Industry;
2.

Reprints Containing Off-Label Information

12

a.

AstraZeneca Scientifically Trained Personnel shall be responsible
for the identification, selection, approval and dissemination of
Reprints Containing Off-Label Information regarding Seroquel.

b.

Requests to proactively disseminate a Reprint Containing OffLabel Information shall be submitted to the appropriate director of
Medical Affairs, who will convene a cross-functional team,
including a representative from Clinical, Medical Affairs,
AstraZeneca’s U.S. Compliance Department, AstraZeneca’s Legal
Department, and Promotional Regulatory Affairs, to examine the
facts and justification for the request to distribute a Reprint
Containing Off-Label Inforpiation on a case-by-case basis.

c.

Reprints Containing Off-Label Information shall:
(i)

be accompanied by the full prescribing information for
the product, or a clearly and conspicuously described
hyperlink that will provide the reader with such
information, and contain a disclosure in a prominent
location, which would include the first page or as a cover
page where practicable, indicating that the article may
discuss Off-Label information; and

(ii)
d.

not be referred to or used in a Promotional manner.

Reprints Containing Off-Label Information regarding Seroquel
may be disseminated only by AstraZeneca Scientifically Trained
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Personnel to HCPs. AstraZeneca Non-SciP shall not disseminate
these materials to HCPs.
3.

Nothing in this Judgment shall preclude AstraZeneca from disseminating

Reprints which have an incidental reference to Off-Label information. If Reprints have an
incidental reference to Off-Label information, such reprints shall contain the disclosure required
by section ILD.2.c.(i) in a prominent location, as defined above, and such incidental reference to
Off-Label information shall not be referred to or used in a Promotional manner as prohibited by
Section il.p.2.c.(ii),
III.

G rants
A.

AstraZeneca shall disclose information about medical education grants,

including CME grants, regarding Seroquel consistent with the current disclosures of MEGO
with a link to the disclosures available through AstraZeneca’s website and as required by .
applicable law,
1.

AstraZeneca shall maintain this information oh the website, once posted*,

for at least two years, or longer if applicable law so requires, and shall maintain the information
in a readily accessible format for review by the States upon written request for a period of five
years.
B.

MEGO shall manage all requests to AstraZeneca for funding related to medical

education grants regarding Seroquel. Approval decisions shall be made by MEGO alone, and
shall be kept separate from the AstraZeneca Sales and AstraZeneca Marketing organizations.
C.

AstraZeneca shall not use medical education grants or any other type of grant to

Promote Seroquel, This provision includes, but is not limited to, the following prohibitions:

14
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1.

i

AstraZeneca Sales and AstraZeneca Marketing personnel shall not initiate,

coordinate or implement grant applications on behalf of any customer or HOP;
2.

AstraZeneca Sales and AstraZeneca Marketing personnel shall not be

involved in selecting grantees or medical education speakers; and
3.

AstraZeneca shall not measure or attempt to track in any way the impact

of grants or speaking fees on the participating HCPs’ subsequent prescribing habits, practices or
patterns.
D.

AstraZeneca shall not condition funding of a medical education program grant

request relating to Sefoquel upon the requestor’s selection or rejection of particular speakers.
E.

AstraZeneca shall not suggest, .control, or attempt to influence selection Of the

specific topic, title, content, speakers or audience for CMEs relating to Seroquel, consistent
with Accreditation Council for Continuing Medical Education Guidelines.
F.

AstraZeneca Sales and AstraZeneca Marketing personnel shall not approve

grant requests relating to Seiroqüel, nor attempt to influence the awarding of grants to any
customers or HGPs for their prescribing habits, practices or patterns.
G.

AstraZeneca shall contractually require the medical education provider to

clearly and conspicuously disclose to medical education program attendees AstraZeneca’s
financial support o f the medical education program and any financial relationship with faculty
and speakers at such medical education program.
H.

After the initial delivery of a medical education program, AstraZeneca shall not

knowingly fund the same program, nor shall it provide additional funding for re-distribution of
the same program, if the program’s speakers are Promoting Seroquel for Off-Label uses in that
program.
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IV.

Payments to Consultants and Speakers
A.

This Section shall be effective Cor five (5) years from the Effective Date of this

Judgment and shall apply to U.S. based Consultants and Promotional Speakers performing
Promotional activities for AstraZeneca.
B.

Phase I Reporting.
1.

AstraZeneca shall continue to post in a prominent position on its website

an easily accessible and readily searchable listing of all U.S.-based physicians and Related
Entities (as defined below in Section IV.D.5) who or which;received Phase I Payments (as
defined below in Section IV.D.2) directly orindireetly from AstraZeneca during the first six
months of 2010 and the aggregate value of such Phase I Payments.
2.

On or before February 28,2011, AstraZeneca shall also post on its website

a listing of updated information about all Phase I Payments provided during the last six months
of 2010, On or before May 3 1, 2011, AstraZeneca shall also post on its website a listing of
updated information about all Phase I Payments provided during the first quarter of 2011, On or
before lime 30,2011, AstraZeneca shall also post on its website a report of the cumulative value
of the Phase I Payments provided to each physician, and/or Related Entity during 2010. The
quarterly, six-month, and annual reports shall be easily accessible and readily searchable.
3.

Each listing made pursuant to this SectionTV. B shall include a complete

list o f all individual physicians and Related Entities to whom or to which AstraZeneca directly or
indirectly made Payments in the preceding six-month period, quarter* or year (as applicable).
Each listing shall be arranged alphabetically according to the physicians9 last name or the name
of the Related Entity. For each physician, the applicable listing shall include the following
information: i) physician’s full name- ii) name of any Related Entities (if applicable); iii) city and
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state that the physician or Related Entity has provided to AstraZeneca for contact purposes; and
(iv) the aggregate value of the payments) in the preceding quarter, six-month period, or year (as
applicable). If payments for multiple physicians have been made to one Related Entity, the
aggregate value of all payments to the Related Entity will be the reported amount.
C.

Phase II Reporting
1.

On or before August 31, 2011, AstraZeneca shall post in a prominent

position on its website an easily accessible and readily searchable listing of all U.S.-based
physicians and Related Entities who or which received Phase II Payments (as defined below in
Section IV.D.3) directly or indirectly from AstraZeneca during the second quarter of 2011 arid
. the aggregate value o f such Phase II Payments.
. 2.

After the August 31,2011 posting, 30 days alter the end of each

subsequent calendar quarter^ AstraZeneca shall post on its website a listing of updated
information about all Phase II Payments provided from the first reporting quarter of the year
through the close of the most recent quarter of the year. Beginning in 2012, on or before May 1
o f each year, AstraZeneca shall also post on its website a report o f the cumulative value of the
Phase II Payments provided to each physician, and/or Related Entity during each preceding
calendar year. The quarterly and annual reports shall be easily accessible and readily searchable.
D.

Definitions and Miscellaneous Provisions
1,

AstraZeneca shall continue to make each annual listing and the most

recent six-month or quarterly listing of Payments available on its website. AstraZeneca shall
retain and make available to each Signatory Attorney General, upon request, relevant business
records sufficient to demonstrate the purpose of the Payment and (where applicable) the
performance of a service by the HCP related to all applicable Payments and to the annual, six-
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month, and/or quarterly listings of Payments. Nothing in this Section IV affects the responsibility
of AstraZeneca to comply with (or liability for noncompliance with) all applicable state laws as
they relate to all applicable Payments made to physicians or Related Entities.
2.

For purposes of Section IV.B, the term “Phase I Payments” is defined as

all fees paid in connection with U.S.-based physicians serving as Promotional Speakers, in the
United States or participating in prerequisite speaker training for such Promotional Speaker
engagements.
3.

For purposes o f Section IV.C, the term; “Phase II Payments” is defined to

include all Phase I Payments and all other “payments or transfers o f Value” as that term is
defined in § 1128G(e)(10) under Section 6002 of the Patient Protection and Affordable Care Act
(“PPACA”) and any regulations promulgated thereunder, The term Phase It Payments includes*
by way o f example, the types of payments or transfers o f value enumerated in §
1128G(a)(l)(A)(vi) of PPACA; The term includes all payments or transfers of value made to
Related Entities on behalf of, at the request of, for the benefit or use of, or under the name of a
physician for whom AstraZeneca would otherwise report a Payment if made directly to the
physician. The term “Phase II Payments” also includes any payments or transfers of value made,
directly by AstraZeneca or by a vendor retained by AstraZeneca to a physician or Related Entity
in connection with, or under the auspices of, a co-promotion arrangement,
4.

The terra “Payments” as used in the definition of Phase I Payments and

Phase II Payments does not include transfers of value or other items that are not included or are
excluded from the definition o f‘‘payment” as set forth in § 1128G(e)(10) under Section 6002 of
PPACA and any regulations promulgated thereunder;
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5.

For purposes of this Section IV, the term “Related Entity” is defined to be

any entity by or in which any physician receiving Payments is employed^ has tenure, or has an
ownèrship interest.
E.

Once the Federal Physician Payments Sunshine Act becomes effective,

AstraZeneca shall comply with thé Federal Physician Payments Sunshine Act, Section 6002 of
the PPACA and it is agreed that AstraZeneca’s compliance with the Physician Payment
Sunshine Provision of PPACA will constitute compliance with Section IV of this Final
Judgment and Consent Decree.
V.

Clinical Research Results
A.

AstraZeneca shall report clinical research regarding Serôquel in ah accurate,

objective and balanced manner as follows and as required by applicable law:
1.

To thé extent permitted by die National Library7o f Medicine and as

required by the FDA Amendments Act o f2007 (Public Law No. 110-85), AstraZeneca shall
register clinical trials and submit clinical trial results to the registry and results data bank
regarding Seroquël as required fay the FDA Amendments Act and any accompanying regulations
that may be promulgated pursuant to that Act. With respect to Seroquel, AstraZeneca registers on
a publicly accessible NIH website ( www.clinicaltrials.govl the initiation o f all AstraZenecasponsored clinical studies involving individuals and posts a summary of the results of all
AstraZeneca-sponsored clinical studies in patients or volunteers for marketed and investigative
products on the above-referenced NIH website and on a company website
("www.astrazenecadinicaltrials.com). Nothing in this paragraph shall be construed to exempt
AstraZeneca from full compliance with Title 22 M.K.S. § 2700-A.
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B.

(

When presenting information about a clinical study regarding Seroquel,

AstraZeneca shall not do any of the following in a manner that causes the Promotional
materials to be false, misleading or deceptive:
1.

present favorable information or conclusions from a study that is

inadequate in design, scope, or conduct to furnish significant support for such information or
conclusions;
2.

use the Concept of statistical significance to support a claim without

providing the appropriate clinical context, or which fails to reveal the range of variations around
the quoted average results;
3.

use statistical analyses and techniques on a retrospective basis to discover

and cite findings not soundly supported by the study, or to suggest scientific validity and rigor .
for data from studies the design or protocol of which are not amenable to formal statistical
evaluations;
4

present the information in a way that implies that the study represents

larger or more general experience with the drug than it actually does;; or
5.

use statistics on numbers of patients, or counts of favorable results or side

effects, derived from pooling data, unless such pooling has been done in a statistically rigorous
manner, pursuant to a protocol, and that the method of pooliiig has been disclosed.
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PAYMENT AND RELEASE PROVISIONS
VL

Terms Relating to Payment
A,

No later than 30 days after the Effective Date of this Judgment, AstraZeneca

shall pay $68.5 million to be divided and paid by AstraZeneca directly to each Signatory
Attorney General o f the Multistate Working Group in an amount to be designated by and in the
sole discretion of the Multistate Executive Committee. The State of Maine’s share of the total
settlement amount may be used for any uses permitted by state law, including, without
limitation, for attorneys’ fees and investigative costs, consumer education, litigation, public
protection and/or local consumer aid funds* at the sole discretion of the Signatory Attorney
General. The Parties acknowledge that the payment described herein is not a fine or penalty,
or payment in lieu thereof.
VÏÏ.

Release
A.

By its execution of this Judgment, the State of Maine releases and forever

discharges AstraZeneca, and all o f its past and. present subsidiaries* divisions, affiliates, copromoters, controlled joint ventures, predecessors, successors, and assigns and each and all of
their current and former officers, directors, shareholders, employees, agents* contractors,and
attorneys (collectively, the “Released Parties”) of and from the following: all civil claims,
causes of action, parens patriae claims, damages, restitution, fines, costs, attorneys fees,
remedies and/or penalties that the Maine Attorney General has asserted or could have asserted
against the Released Parties under the Maine Unfair Trade Practices Act or any amendment
thereto, or common law claims concerning unfair, deceptive, or fraudulent trade practices
resulting from thé Covered Conduct up to and including the Effective Date (collectively, the
“Released Claims”).
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B.

Notwithstanding any term of this Judgment, specifically reserved and excluded

from the Released Claims as to any entity or person, including Released Parties, are any and all
of the following:
1.

Any criminal, liability that any person or entity, including Released Parties,

has or may have to the State of Maine;
2.

Any civil or administrative liability that any person or entity, including

Released Parties, has Or may have to the State of Maine not expressly covered by the release in
Section VILA above, including, but not limited to, any and all of the following claims:
a.

State or federal antitrust violations;

b.

Claims involving “best price,’’ “average wholesale price” or
‘^wholesale acquisition cost;”

c.

Medicaid violations, including but not limited to federal Medicaid
drug rebate statute violations, Medicaid fraud or abuse, and/or
kickback violations related to any state’s Medicaid program; and

d.
3.

State false claims violations,

Actions Of state program payors of the State of Maine arising from the

purchase o f Seroquel, except for the release of civil penalties under the state consumer protection
laws cited in footnote 3*
4.

Any claims individual consumers have or may have under the State of

Maine’s above cited consumer protection laws against any person or entity, including Released
Parties.
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PROVISIONS RELATED TO OTHER LAWS AND DISPUTE RESOLUTION
V in . Conflicts with Other Laws
A.

This Judgment (or any portion thereof) shall in no way be construed to prohibit

AstraZeneca from making representations with respect to Seroquel that are permitted under
Federal law or in Labeling for the drug under the most current draft or final standard
promulgated by the FDA or the most current draft or final FDA Guidances for Industry, or
permitted or required under any Investigational Nfew Drug Application, New Drug Application,
Supplemental New Drug Application, or Abbreviated New Drug Application approved by FDA,
unless facts are or become known to AstraZeneca that such representation, taken in its entirety, is
false, misleading or deceptive.

Nothing in this paragraph should be interpreted to excuse

AstraZeneca from implementing any o f the affirmative obligations described in the Compliance
Provisions o f this Judgment. If, subséquent to the Effective Date of this Judgment, the laws or
regulations of thé United States are. changed so as to expressly authorize conduct that is
expressly prohibited by this judgment, then such conduct shall not constitute a violation Of this
judgment Provided however, if AstraZeneca intends to engage in the expressly authorized
conduct, AstraZeneca shall notify the Attorneys General (or the Attorney General of the affected
state) within 30 business days prior to engaging in the expressly authorized conduct.
B.

If, subsequent to the Effective Date of this Judgment, the federal government or

any state, Or any federal or state agency, enacts or promulgates legislation, regulations, or
guidances with respect to matters governed by this Judgment that creates a conflict with any of
the Compliance Provisions of the Judgment and AstraZeneca intends to comply with the newly
enacted legislation, regulation, or guidance, AstraZeneca shall notify the Attorneys General (or
the Attorney General of the affected State) of the same. If the Attorney General agrees, he/she
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shall consent to a modification of such provision of the Judgment to the extent necessary to
eliminate such conflict. If any Attorney General disagrees and the Parties are not able to
resolve the disagreement* AstraZeneca shall seek a modification from an appropriate court of
any provision of this Judgment that presents a conflict with any such federal or state law,
regulation, or guidance. The disagreement of an Attorney General shall in no way impact
AstraZeneca’s ability to take action in any state and/or territory not represented by that
Attorney General. Changes in federal dr state laws, regulations, or guidances with respect to
the matters governed by this Judgment shall not be darned to create a conflict with a provision
of this Judgment unless AstraZeneca cannot reasonably comply with both such law, regulation,
or guidance and the applicable provision o f this Judgment
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IX.

Dispute Resolution
A.

For the purposes of resolving disputes with respect to compliance with this

Judgment, should any of the Signatory Attorneys General have a reasonable basis to believe that
AstraZeneca has engaged in a practice that violates a provision of this Judgment subsequent to
the Effective Date of this Judgment, then Such Attorney General shall notify AstraZeneca in
writing of the specific objection, identify with particularity the provisions of this Judgment that
the practice appears to violate, and give AstraZeneca thirty (30) days to respond to the
notification; provided, however, that a Signatory Attorney General may take any action if the
Signatory Attorney Geheral concludes that, because of the specific practice, a threat to the health
or safety of the public requires immediate action. Upon receipt of written notice, AstraZeneca
shall provide a good-faith written response to the Attorney General notification, containing either
a statement explaining why AstraZeneca believes it is in compliance with the Judgment, or a
detailed explanation of how the alleged violation occurred and statement explaining how and
when AstraZeneca intends to remedy the alleged violation* Nothing in this paragraph shall be
interpreted to limit the State’s Civil Investigative Demand (“CID”) or investigative subpoena
authority, to the extent such authority exists under applicable state law, and AstraZeneca reserves
all of its rights with respect to a CID or investigative subpoena issued pursuant to such authority.
B,

Upon giving AstraZeneca thirty (30) days to respond to the notification described

above, the Signatory Attorney General shall also be permitted reasonable access to inspect and
copy relevant, non-priyileged, non-work product records and documents in the possession,
custody or control o f AstraZeneca that relate to AstraZeneca’s compliance with each provision
of this Judgment as to which cause that is legally sufficient in the State has been shown.
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C.

f

If the Signatory Attorney General makes or requests copies of any documents

during the course of that inspection, the Signatory Attorney General will provide a list of those
documents to AstraZeneca, Any and all documents and information (including, but not limited
to, electronic information) provided in response to a request by the State shall be protected to the
extent provided by the requesting State’s Freedom of Information Act or other state law. Such
documents or information shall not be disclosed by the State to any other party or entity
(pursuant to a FOIA request, subpoena, or otherwise) Without first providing notice to
}
AstraZeneca, to the extent allowed by law, so that AstraZeneca may take necessary steps to
protect its confidential documents or information prior to disclosure.
D.

The State of-M aine may assert any claim that AstraZeneca has violated, this

Judgment in that State in a separate civil action to enforce compliance with this Judgment, or
may seek any other relief afforded by law, but only after providing AstraZeneca an opportunity
to respond to the notification described in Paragraph IX.A. above, provided, however, that a
Signatory Attorney General may take any action if the Signatory Attorney General concludes
that, because of the specific practice, a threat to the health Or safety of the public of that State
requires immediate action.
X*

Timely W ritten Requests for Extensions
Nothing will prevent the State from agreeing in writing to provide AstraZeneca with

additional time to perform any act or to file any notification required by the Judgment. The
Attorney General shall not unreasonably withhold his/her agreement to the request for additional
time.
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XI.

(

General Provisions
A.

AstraZeneca shall not cause or encourage third parties* nor knowingly permit

third parties acting on its behalf, to engage in practices from which AstraZeneca is prohibited
by this Judgment;
B.

This Judgment represents the full and complete terms of the settlement entered

into by the Parties hereto. In any action undertaken by the Parties, neither prior versions of this
Judgment, nor prior versions of any of its terms, that were not entered by the Court in this
Judgment, may be introduced for any purpose whatsoever.
C.

This Court retains jurisdiction of this Judgment arid the Parties hereto for the

purpose of enforcing and modifying this Judgment and for the purpose o f granting such
additional relief as may be necessary and appropriate,
D.

This Judgment may be executed in counterparts, and a facsimile or .pdf

signature shall be deemed to be, and shall have the same force and effect as, an original
signature.
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E.

AH Notices under this Judgment shall be provided to John C. Dodds and the

U.S. Compliance Officer of AstraZeneca by Overnight Mail at:

John C. Dodds
Morgan, Lewis & Bockius LLP
1701 Market S t
Philadelphia, PA 19103
Marie L. Martino
U.S. Compliance Officer
AstraZeneca
1800 Concord Pike
PO Box 15437
Wilmington,DE 19850-5437
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PLAINTIFF, THE STATE OF MAINE
WILLIAM J. SCHNEIDER
Maine Attorney General
Date:
. . . . „ . ,. .
„ 3eneral
Maine Bar No. 7095
Office of the Maine Attorney General
6 State House Station
Augusta, Maine 04333-0006
(207) 626-8838.
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ASTRAZENECA PHARMACEUTICALS LP and ASTRAZENECA LP

By:
Marie L. Martino
U.S. Compliance Officer
AstraZeneca
1800 Concord Pike
PO Box 15437
Wilmington, DE 19850-5437
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Approved as to form:

Date:

3 //£ > /2 0/7

JhM C. Dodds
Morgan, Lewis & Bockius LLP
1701 Market S t
Philadelphia, PA 19103-2921
215.963,4942
215.963,5001-Fax
jdodds@morganlewis.com

Attorney for AstraZeneca Pharmaceuticals LP arid AstraZeneca LP
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By:

VkUfr

Date: itfa tb L ' / ,

Walier Judge
Downs, Rachlin Martin PLLC
199 Main Street
P.O.Box 190
Burlington, YT 05402-0190
802.846.8326
wiudge@dnn.com

Attorney for AstraZeneca Pharmaceuticals LP and AstraZeneca LP
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APPROVED BY THE COURT:

\i t i

JUSTICp, INAINE SUPERIOR COURT

Date Entered:

z ji^ j l f
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